| Literature DB >> 29880785 |
Michal Pawlak1, Katarzyna Niescierowicz2, Cecilia Lanny Winata3,4.
Abstract
: Vertebrate organs develop through a complex process which involves interaction between multiple signaling pathways at the molecular, cell, and tissue levels. Heart development is an example of such complex process which, when disrupted, results in congenital heart disease (CHD). This complexity necessitates a holistic approach which allows the visualization of genome-wide interaction networks, as opposed to assessment of limited subsets of factors. Genomics offers a powerful solution to address the problem of biological complexity by enabling the observation of molecular processes at a genome-wide scale. The emergence of next generation sequencing (NGS) technology has facilitated the expansion of genomics, increasing its output capacity and applicability in various biological disciplines. The application of NGS in various aspects of heart biology has resulted in new discoveries, generating novel insights into this field of study. Here we review the contributions of NGS technology into the understanding of heart development and its disruption reflected in CHD and discuss how emerging NGS based methodologies can contribute to the further understanding of heart repair.Entities:
Keywords: ChIP-seq; GWAS; RNA-seq; congenital heart disease; epigenetics; genomics; heart development; heart regeneration; next generation sequencing; whole exome sequencing
Year: 2018 PMID: 29880785 PMCID: PMC6027153 DOI: 10.3390/genes9060289
Source DB: PubMed Journal: Genes (Basel) ISSN: 2073-4425 Impact factor: 4.096
Figure 1Genome-wide studies at different stages of heart development. Next Generation sequencing (NGS) studies at different stages of heart development facilitate the discovery of transcriptional regulators including transcription factors (TFs), enhancers as well as long non coding RNA (lncRNA), enhancer-associated lncRNAs (elncRNA), microRNA (miRNA), and chromatin modifiers driving stage-specific processes of cardiac development from early cardiac progenitor cells (CPs) differentiation up to heart maturation. AS: alternative splicing; circRNA: circular RNA; CMs: cardiomyocytes; EMT: epithelial to mesenchymal transition [4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21].
Whole exome sequencing (WES)-identified genes affected in patients with diagnosed congenital heart disease (CHD).
| Heart Malformation | Identified Disease Genes | Reference |
|---|---|---|
| 362 parent-offspring trios with severe CHD (excluded isolated ventricular septal defects, atrial septal defects, patent ductus arteriosus and pulmonic stenosis) and 264 control trios | Genes involved in production, removal and reading of methylation of H3K4 (H3K4me): | [ |
| 2871 CHD cases including parent-offspring trios and 1789 controls | [ | |
| 715 CHD parent-offspring trios and 416 healthy individuals | Mosaic | [ |
| TOF, combined with Cleft Lip and Palate | G586A and G196S variant of | [ |
| 8 TOF families | Novel causative mutations of | [ |
| 4 families with ASD, 2 families with PDA, 2 families with TOF and 1 family with dysplastic pulmonary valve | [ | |
| 4-generation ASD family | Novel | [ |
| 79 subjects with BAV | [ | |
| Left-sided lesions | 17 genes not previously associated with human cardiovascular malformation including | [ |
| 181 individuals from 41 families with LVOTO | [ | |
| 32 BAV patients | [ | |
| Twins with heterotaxy |
| [ |
| 1,365 trios with CHD, 68 probands from 32 multisibling families, and 458 singleton probands, 12,031 controls | [ | |
| 59 CHD trios and 59 control trios, | Novel | [ |
| 3 family members with LVNC | Novel genetic variant of | [ |
ASD: atrial septal defects; AVSD: atrioventricular septal defect; BAV: bicuspid aortic valve; LVNC: left ventricular non-compaction; LVOTO: left-ventricular outflow tract obstructions; TOF: tetralogy of Fallot.
Figure 2Insights into heart regeneration gained from NGS-based studies. Different approaches for cardiac injury induction in adult zebrafish (upper) and neonatal and adult mouse used to investigate heart regeneration. NGS studies on cardiac repair in lower vertebrates (zebrafish) and mammals (mouse) have identified molecular regulators including driving genes, enhancers, miRNA, as well as cellular and environmental factors directing efficient heart regeneration [73,74,75,76,77,78,79,80].
Figure 3Perspective integrative genomic studies that may contribute to our understanding of molecular mechanisms of heart development and regeneration. The integration of transcriptomic (RNA-seq, scRNA-seq) and epigenetic (chromatin immunoprecipitation followed by high throughput sequencing (ChIP-seq), assay for transposase-accessible chromatin with sequencing (ATAC-seq), HiC, bisulfite sequencing (BS-seq), 5-hydroxymethylcytosine sequencing (5hmc-seq)) studies from model organisms with clinical data from congenital heart disease (CHD) patients (Whole exome sequencing (WES) or targeted genome sequencing) can provide novel insights into our understanding of molecular mechanisms driving heart development and the identification of genetic factors responsible for cardiac developmental anomalies. Integrative Genomics (IG).